Syneos Health, Inc.

Seasoned Biotech Executive Further Strengthens Company’s Leadership Team Sandy Loreaux, former CEO, to Remain on Board of Directors LEBANON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Bryn Pharma, LLC, a privately held pharmaceutical company dedicated to finding a novel and convenient way for patients and caregivers to treat anaphylaxis, today announced that Joshua Ziel, Ph.D., has been appointed Chief Executive Officer (CEO) and member of the Board of Directors. Sandy Loreaux is stepping down as CEO for family-related reasons but will remain on Bryn Pharma’s Board of Directors to continue to help guide company strategy. Dr. Ziel is a seasoned biotech executive and founder who brings to Bryn Pharma deep and relevant expertise in inhalation product development and a proven track record crafting strategies for product differentiation, launch, and commercialization across categories. Before joining Bryn Pharma, he served as the Chief Operating Officer of Aerami Therapeutics, where he was responsible for multiple aspects of corporate and pipeline development, ranging from R&D to business development. In that role, he spearheaded the clinical development program to enhance the company's portfolio of inhaled products in pulmonary hypertension and successfully drove key clinical and regulatory milestones for the company's lead asset. Prior to Aerami, Josh held senior executive roles in the contract research organization (CRO) sector at Syneos Health and within the WPP agency network. “We are pleased to welcome Josh to our team and leverage his extensive background in corporate strategy, R&D, and operations as we advance NDS1C towards FDA approval and commercialization,” said Michelle Lobel, co-founder and board member of Bryn Pharma. “He has an impressive and well-rounded background that will be a strong asset for Bryn Pharma’s growth. On behalf of the Board, I would also like to thank Sandy Loreaux for her leadership and look forward to her continued contributions to our Board.” “I am excited to join Bryn Pharma as we finalize the regulatory pathway and commercial strategy for NDS1C,” said Joshua Ziel, Chief Executive Officer. “There is an incredible potential with NDS1C to bring patients best-in-class, needle-free epinephrine administration for anaphylaxis that is comparable to the EpiPen, and I look forward to working with Sandy to build on the momentum established by the impressive team at Bryn Pharma.” “I am confident in Josh’s expertise and leadership, and I look forward to working closely with him as we continue to advance NDS1C toward regulatory approval.” stated Steven Hartman, co-founder and chairman of the Bryn Pharma Board of Directors. “We have a significant opportunity to differentiate our product in the large and growing epinephrine market and Bryn Pharma is well positioned to deliver on the profound unmet need in this space.” About NDS1CIf approved, NDS1C will offer patients a needle-free nasal delivery system for emergency epinephrine, an area that hadn’t seen significant innovation in decades until recently. Bryn Pharma is dedicated to creating a novel and practical solution to help this community address these challenges and better manage their daily lives. About Bryn Pharma Bryn Pharma, established in 2017, is a privately held pharmaceutical company founded by patients for patients. Bryn Pharma is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, needle-free, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk with a novel and practical way to prepare for a potential life-threatening allergic reaction. For more information visit www.brynpharma.com. Investor Contact: LifeSci AdvisorsJeremy FefferJFeffer@LifeSciAdvisors.com

– Karl Deonanan appointed Chief Financial Officer – – Matt DeZee named to newly established role, Chief Transformation and Strategy Officer – BETHESDA, Md., Oct. 23, 2024 /PRNewswire/ -- Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, today announced key leadership changes to support its next phase of growth. This includes the appointment of Karl Deonanan as Chief Financial Officer (CFO). Mr. Deonanan succeeds Matt DeZee, who has served as CFO of Precision since 2020 and will be transitioning to the newly created role of Chief Transformation and Strategy Officer (CTSO), effective immediately. Continue Reading Precision Medicine Group today announced key leadership changes to support its next phase of growth. Post this Precision Medicine Group is a leading next-generation provider of drug development and commercialization services. Karl Deonanan - Chief Financial Officer Matt DeZee - Chief Transformation and Strategy Officer "Since its inception in 2012, Precision's success has been enabled by its people – a global team of experts spanning the clinical through commercial continuum who are committed to delivering innovative, best-in-class services to support life science organizations from molecule to market," said Margaret Keegan, Chief Executive Officer of Precision. "With today's appointments, we are bolstering our executive leadership team – and welcoming an experienced financial leader with a proven track record of scaling high growth organizations. I look forward to Karl and Matt's contributions as we continue to grow Precision and strategically assimilate the next wave of technological advancements to improve the development, manufacture and launch of new life-changing medicines." In their new roles, Mr. Deonanan will be responsible for all finance and accounting functions, and Mr. DeZee will lead strategic growth and operational optimization, enhancing how Precision serves a global suite of clients. Both have oversight across Precision's two groups: Precision for Medicine, the premier provider of biomarker-driven clinical research and development, including integrated lab and clinical trial services; and Precision AQ, the foremost provider of commercialization services supporting life science organizations from launch through product maturity. Karl Deonanan, Chief Financial Officer Mr. Deonanan joins Precision with nearly 30 years of finance and accounting experience and over 20 years leading life science services organizations. Most recently, he was CFO at ProPharma Group, a multi-unit life science services organization and, before that, he held executive-level financial leadership roles at X-Chem, Inc., Synteract and IQVIA. In these roles, Mr. Deonanan led organizations ranging in size from $100 million to $3.5 billion in revenue with up to 30,000 employees across over 60 countries, partnered with both private and public investors and led complex systems implementations, innovative strategic partnering arrangements and initial public offerings. Mr. Deonanan holds an M.S. in Accounting from East Carolina University and a B.S. in Accounting from the University of North Carolina Wilmington. Mr. Deonanan commented, "I could not be more excited to join Precision at this inflection point in the company's history. Precision has built a truly unique platform pointed at the future of both drug development and commercialization. I look forward to contributing to the next generation of innovation for our clients and the patients they serve." Matt DeZee, Chief Transformation and Strategy Officer A member of Precision's founding team, Mr. DeZee served as Corporate Development Officer for eight years before becoming CFO in 2020. Prior to joining Precision, he held leadership roles at United BioSource Corporation (UBC,) a global team of 1,300 scientists, researchers, clinical data managers and reimbursement experts focused on generating real-world evidence in support of drug manufacturers and patients worldwide. Throughout his time at Precision, Mr. DeZee has played a key role in architecting the organization's growth, leading M&A, global geographic expansions and digital transformation. He holds a B.A. in Economics from the University of Maryland. Mr. DeZee added, "When we started this company in 2012, we knew there was an unmet need for innovators developing the next generation of treatments. Operational optimization and digital transformation help us provide the speed our clients are seeking. I'm excited to lead the adoption of new technologies to enhance and expand our solutions to accelerate the development and commercialization of new therapies." About Precision Medicine Group Formed in 2012, Precision Medicine Group is a specialized services company supporting next-generation approaches to drug development and commercialization. Precision provides an integrated infrastructure that supports pharmaceutical and life science companies as they develop new products in the age of precision medicine. The company is headquartered in Bethesda, Maryland, with offices throughout North America, Europe and Asia. For more information, visit precisionmedicinegrp.com. Media Contact: Contact Hannah Deresiewicz Precision AQ [email protected] SOURCE Precision Medicine Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VANCOUVER, Washington, Oct. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it has engaged Syneos Health as the contract research organization (“CRO”) for its upcoming Phase II oncology trial. The trial will evaluate the efficacy of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer (“CRC”). Syneos Health is a leading fully integrated biopharmaceutical solutions organization that supports customers in accelerating the delivery of life-saving therapies to market. Syneos Health leverages advanced data analytics and AI/ML capabilities to improve outcomes at every stage of the asset lifecycle, from clinical development to commercialization. Syneos Health has helped to develop or commercialize 92% of novel new drugs approved by the FDA in the last five years (2019-2023) and 91% of products granted marketing authorization by the European Medicines Agency. “Investigating leronlimab in the field of oncology remains our top priority, and we are excited to further invest in our promising relationship with Syneos Health. With this expanded mandate, we expect to generate clinical data affirming the utility of leronlimab in combination with trifluridine plus tipiracil (TAS-102) and bevacizumab,” said Dr. Jacob Lalezari, CEO. As previously announced, the Company’s final study protocol was submitted to the FDA for approval in September 2024, and CytoDyn expects to start screening patients in early 2025. About CytoDyn CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. Leronlimab is being studied for oncology and inflammation, as well as other potential indications, including but not limited to HIV and MASH. About Syneos Health Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. Syneos Health translates unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. Syneos Health brings a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together, Syneos Health shares insights, uses the latest technologies and applies advanced business practices to speed its customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment. To learn more about how Syneos Health is shortening the distance from lab to life®, visit syneoshealth.com. Note Regarding Forward-Looking Statements This news release contains forward-looking statements relating to, among other things, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2024, including the section captioned “Forward-Looking Statements” and in Item 1A. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments. CONTACT CytoDynInvestor Relations CytoDyn Inc. ir@cytodyn.com